The data behind this list comes from Dakota Marketplace, the global private markets intelligence platform used by thousands of investment professionals to research LPs, GPs, and private companies. Built by fundraisers for fundraisers, Dakota Marketplace delivers complete, accurate, and daily-updated intelligence across every allocator channel, from family offices and RIAs to sovereign wealth funds and public pensions. Learn More | Book a Demo
For deal sourcers, staying current on private company activity is critical to spotting active buyers, tracking market trends, and uncovering emerging investment opportunities ahead of competitors.
In June alone, we added more than 1,500 new private company transactions, bringing the total to over 25,700 searchable deals across sectors, industries, and transaction types in Dakota Marketplace.
Inside Dakota Marketplace, you’ll find the transactions tab that provides structured, filterable data on deal types, values, and dates, while our editorial team curates daily updates through the dakota transactions newsletter, helping you cut through the noise and focus on what matters most.
To ensure the most comprehensive coverage of private market activity, Dakota monitors over 10,000 websites including company websites, newswires, and numerous third-party news providers to capture and verify transaction data as it happens.
Below are the top 10 health care transactions.
- Transaction Date: 6/22/2026
- Industry: Biotechnology
- Type: Acquisition / Merger
- Transaction Value: $10.9B
Italian pharmaceutical company Angelini Pharma has agreed to acquire Nasdaq-listed Catalyst Pharmaceuticals for $31.50 per share in cash — a 21% premium — totaling approximately $4.1 billion, with the deal expected to close in Q3 2026. The acquisition gives Angelini Pharma a significant U.S. commercial foothold in rare neurological diseases, adding Catalyst's FDA-approved portfolio including treatments for Lambert-Eaton myasthenic syndrome, Duchenne Muscular Dystrophy, and epilepsy.
- Transaction Date: 6/9/2026
- Industry: Biotechnology
- Type: Acquisition / Merger
- Transaction Value: $10.6B
GSK will acquire Nuvalent, a Boston-based clinical-stage biopharmaceutical company, via a tender offer at $124 per share in cash, gaining three lung cancer assets including late-stage ROS1 inhibitor zidesamtinib and ALK inhibitor neladalkib. The deal expands GSK's oncology pipeline with near-term launch potential pending FDA approval, and is expected to close in the third quarter of 2026 subject to customary closing conditions.
- Transaction Date: 6/10/2026
- Industry: Health Care Equipment & Supplies
- Type: Acquisition / Merger
- Transaction Value: $9.9B
Danaher agreed to acquire Masimo Corporation, a specialty diagnostics provider of pulse oximetry and patient monitoring solutions, for $180.00 per share in cash, with Masimo continuing to operate under its own brand as a standalone unit within Danaher's Diagnostics segment. The deal strengthens Danaher's acute-care monitoring capabilities and closed on June 10, 2026, following regulatory approval.
- Transaction Date: 6/1/2026
- Industry: Health Care Providers & Services
- Type: Acquisition / Merger
- Transaction Value: $2.4B
Servier will acquire the muscular dystrophy business of Edgewise Therapeutics for up to $2.65 billion, including a $1.55 billion upfront payment plus up to $1.1 billion in regulatory and commercial milestones, gaining sevasemten, a late-stage investigational treatment for Becker and Duchenne muscular dystrophies. The deal advances Servier's rare neurology ambitions and is expected to close in the third quarter of 2026, pending regulatory clearance.
- Transaction Date: 6/17/2026
- Industry: Biotechnology
- Type: Acquisition / Merger
- Transaction Value: $2.45B
Bayer completed its acquisition of Perfuse Therapeutics, gaining full rights to PER-001, a first-in-class sustained-release endothelin receptor antagonist in Phase II development for glaucoma and diabetic retinopathy, for a $300 million upfront payment plus success-based milestones. The deal strengthens Bayer's ophthalmology pipeline and closed following antitrust clearance and Perfuse stockholder approval.
- Transaction Date: 6/4/2026
- Industry: Biotechnology
- Type: Acquisition / Merger
- Transaction Value: $2.18B
Gilead Sciences completed its acquisition of Ouro Medicines, a clinical-stage biotech developing T cell engager therapies for autoimmune diseases, for $1,675 million upfront plus up to $500 million in contingent milestones, gaining gamgertamig (OM336), a BCMAxCD3 T cell engager for autoimmune hemolytic anemia and immune thrombocytopenia. Galapagos will split the upfront payment and milestones with Gilead, absorb Ouro's operating assets and team, and lead early-stage development while Gilead retains worldwide commercialization rights.
- Transaction Date: 6/8/2026
- Industry: Pharmaceuticals
- Type: Acquisition / Merger
- Transaction Value: $2B
Incyte agreed to acquire Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics, for $1.25 billion upfront plus up to $750 million in sales-based milestones, gaining VGA039, a Phase 3 monoclonal antibody targeting Protein S for von Willebrand disease. The deal expands Incyte's hematology portfolio and is expected to close in the third quarter of 2026, pending Hart-Scott-Rodino antitrust review.
- Transaction Date: 6/15/2026
- Industry: Health Care Providers & Services
- Type: Buyout / Private Equity
- Transaction Value: $1.8B
THL Partners completed a majority investment in Celerion, a global clinical pharmacology and bioanalytical sciences CRO, for $1.8 billion, acquiring the business from H.I.G. Capital's Advantage strategy. The deal supports Celerion's continued expansion of its clinical and bioanalytical capabilities and closed in June 2026.
- Transaction Date: 6/9/2026
- Industry: Health Care Equipment & Supplies
- Type: Buyout / Private Equity
- Transaction Value: $1.45B
Eli Lilly announced agreements to acquire three infectious disease companies — Curevo (up to $1.5B), LimmaTech Biologics (up to $780M), and Vaccine Company (up to $1.55B) — totaling up to $3.83 billion to build a vaccine-focused pipeline. The deals target viral pathogens linked to neurological and oncological risk, as well as antibiotic-resistant bacterial infections, reflecting Lilly's strategy of preventing disease upstream rather than treating its downstream consequences.
- Transaction Date: 6/12/2026
- Industry: Biotechnology
- Type: Acquisition / Merger
- Transaction Value: $1.23B
Otsuka, through its subsidiary Otsuka America, Inc., acquired Transcend Therapeutics for $700 million upfront plus up to $525 million in sales-milestone payments, gaining TSND-201, a Phase 3 rapid-acting neuroplastogen in development for PTSD. The deal advances Otsuka's psychiatric and neurological pipeline and closed on June 12, 2026, following customary closing conditions.
At Dakota, we understand how important it is to stay current on deal activity as it happens. That’s why our editorial team continuously monitors the news for real-time updates on platform investments, add-ons, divestitures, and more to deliver daily highlights straight to your inbox through our transactions newsletter.
Inside Dakota Marketplace, the transactions tab provides structured, filterable data with deal dates, types, sectors, and financials, allowing you to build a customized feed that aligns with your focus areas.
Whether you're evaluating a new investment opportunity or tracking trends within a target sector, Dakota Marketplace helps you cut through the noise and focus on what matters most.
For more information on these transactions and a deeper dive into their industries and sub-industries, book a demo of Dakota Marketplace.
